Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00571558 · ClinicalTrials.gov registry record · Phase 1
Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT00571558: Clinical Trial Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00571558 is a Phase 1 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00571558, a Phase 1 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is active, abnormal cells are killed. Photodynamic therapy using aminolevulinic acid may be effective against oral leukoplakia.
Interventions
- OTHER laboratory biomarker analysis
- DRUG aminolevulinic acid hydrochloride
- DRUG photodynamic therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00571558
The ClinicalTrials.gov registry entry for NCT00571558 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00571558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00571558 about?
NCT00571558 is a clinical study titled "Photodynamic Therapy Using Aminolevulinic Acid in Treating Patients With Oral Leukoplakia". This phase I trial studies the side effects and best dose of photodynamic therapy using aminolevulinic acid in treating patients with oral leukoplakia. Photodynamic therapy uses a drug, such as aminolevulinic acid, that becomes active when it is exposed to a certain kind of light. When the drug is a...
What is the current status of trial NCT00571558?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2008-03. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00571558?
The interventions under investigation include: laboratory biomarker analysis (OTHER), aminolevulinic acid hydrochloride (DRUG), photodynamic therapy (DRUG).
Who is sponsoring clinical trial NCT00571558?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.